| Literature DB >> 18354737 |
Jayalakshmi Krishnan1, Gwang Lee, Sang-Uk Han, Sangdun Choi.
Abstract
Understanding the molecular pathways mediating neuronal function in retinas can be greatly facilitated by the identification of genes regulated in the retinas of different mutants under various light conditions. We attempted to conduct a gene chip analysis study on the genes regulated during rhodopsin kinase (Rhok-/-) and arrestin (Sag-/-) knockout and double knockouts in mice retina. Hence, mice were exposed to constant illumination of 450 lux or 6,000 lux on dilated pupils for indicated periods. The retinas were removed after the exposure and processed for microarray analysis. Double knockout was associated with immense changes in gene expression regulating a number of apoptosis inducing transcription factors. Subsequently, network analysis revealed that during early exposure the transcription factors, p53, c-MYC, c-FOS, JUN, and, in late phase, NFkappaB, appeared to be essential for the initiation of light-induced retinal rod loss, and some other classical pro- and antipoptotic genes appeared to be significantly important as well.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18354737 PMCID: PMC2267252 DOI: 10.1155/2008/327468
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1Number of upregulated and downregulated genes in wild-type and rhodopsin kinase/arrestin knock-out (Rhok−/−/Sag−/−) after dark adaptation for indicated periods.
Significant or specific regulations in early stage of Rhok−/−/Sag−/− mutant. L0: low light for 0 hour in wild-type; L1: low light for 1 hour in wild-type; and so on. H0, high light for 0 hour in wild-type; H1: high light for 1 hour in wild-type; and so on. M0: low light for 0 hour in Rhok−/−/Sag−/− mutant; M1: low light for 1 hour in Rhok−/−/Sag−/− mutant; and so on. The numbers are in log2 ratio. Refer to the text for details.
| Gene Name | Accession | L0 | L1 | L3 | L5 | L12 | L20 | H0 | H1 | H3 | H5 | H16 | H24 | M0 | M1 | M3 | M5 | M7 | M9 | M12 | M16 | M20 | M24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBJ osteosarcoma oncogene | V00727 | 2.8 | 1 | 0 | 1.6 | 1.5 | 0 | 2 | 1.5 | 3 | 3.4 | 2.2 | 0.7 | 1.5 | 1.4 | 2.5 | 1.9 | 2.5 | 2.6 | 2.1 | 2.1 | 1.7 | 1.1 |
| connective tissue growth factor | M70642 | 0.9 | 0 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4 | 0 | −1.3 | 1.1 | 1.8 | 1.1 | 1 | 1.9 | 1.7 | 1.6 | 1.9 | 1.3 | 1.3 |
| CCAAT/enhancer binding protein (C/EBP), delta | X61800 | 0 | 0 | 0 | 0 | −0.6 | −0.5 | 0 | 0 | 2.6 | 3.6 | 3 | 2.9 | 1.1 | 0 | 2.5 | 2.9 | 3.6 | 4.2 | 4 | 4.1 | 4 | 4.3 |
| early growth response 1 | M28845 | 2.5 | 0 | 1.1 | 1.8 | 1.5 | 0 | 0 | 2.3 | 3 | 3.2 | 1.6 | 0 | 1 | 1.4 | 2.8 | 1.5 | 2.4 | 2.9 | 2.4 | 2.4 | 1.4 | 0.6 |
| prostaglandin D2 synthase (21 kDa, brain) | AB006361 | −0.7 | −0.8 | 0 | −0.8 | −0.5 | −0.3 | 0 | 1 | 1.2 | 0.9 | 0 | −0.3 | 0.9 | 1 | 1.2 | 1 | 0.9 | 0.5 | 0.9 | 1.1 | 0.8 | 0.6 |
| brain derived neurotrophic factor | X55573 | 0.6 | 0 | 0 | 0 | 0 | 0 | 1 | 0.8 | 0 | 1.3 | 1.4 | 0.6 | 0.9 | 0 | 0 | 0 | 1 | 1.2 | 0.8 | 1.2 | 0.6 | 0.9 |
| nuclear receptor subfamily 4, group A, member 1 | X16995 | 2.1 | 0.7 | 0 | 0.4 | 0.7 | 0 | 1.3 | 0 | 0 | 1.2 | 0 | 0 | 0.9 | 0 | 0 | 0 | 0 | 0.4 | 0.5 | 0.6 | 0.9 | 0 |
| prostaglandin D2 synthase (21 kDa, brain) | AB006361 | −0.5 | −1 | 0.4 | −0.8 | −0.8 | −0.4 | 0.6 | 1 | 1.3 | 1.1 | 0 | 0 | 0.8 | 1.2 | 1.2 | 0.5 | 0.7 | 0.6 | 1 | 1.1 | 0.9 | 0.8 |
| activating transcription factor 4 | M94087 | 1 | 1 | 0.5 | 0 | 0 | 0 | 0.7 | 0.7 | 0 | 0 | 0 | 0 | 0.7 | 1.2 | 1.3 | 1.2 | 1.1 | 0.6 | 0.6 | 0.5 | 0 | 0 |
| retinol binding protein 1, cellular | X60367 | 0 | −0.4 | 0 | −0.4 | 0 | 0 | 0.6 | 0.9 | 0.6 | 0.9 | 1 | 0.6 | 0.7 | 0.6 | 0.6 | 0 | 0.9 | 1.3 | 1.8 | 2.2 | 1.9 | 2.4 |
| metallothionein 2 | K02236 | 0 | 0 | 0.9 | 0 | 0 | 0 | 0 | 1.4 | 2 | 3.7 | 0 | 1.2 | 0.6 | 1.2 | 2.5 | 2.6 | 4 | 3.8 | 4.1 | 3.7 | 3.1 | 2.7 |
| metallothionein 1 | V00835 | 0 | 0.6 | 1 | 0.4 | −0.4 | 0 | 0 | 0.9 | 1.7 | 3 | 1 | 0.8 | 0 | 1.1 | 2.1 | 2.5 | 3.7 | 3.8 | 3.7 | 4 | 2.6 | 2.6 |
| Bcl2-associated athanogene 3 | AV373612 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7 | 2.8 | 0 | 0 | 0 | 0 | 5.2 | 0 | 6.4 | 6.6 | 6 | 6.8 | 6.1 | 6.2 |
| fos-like antigen 1 | AF017128 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.2 | 0 | 0 | 0 | 0 | 3.7 | 0 | 4.6 | 4.8 | 4.9 | 4 | 3.7 | 0 |
| growth arrest and DNA-damage-inducible 45 beta | AV138783 | 1.2 | 0.9 | 0 | 0 | 0 | 0 | 1.3 | 1.1 | 2.2 | 3.3 | 3 | 2 | 0 | 0 | 3.1 | 2 | 3.6 | 4.4 | 4.5 | 4.2 | 3.7 | 3.5 |
| activating transcription factor 3 | U19118 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2.9 | 2.5 | 2.3 | 2.6 | 2.7 | 2.9 | 2.7 |
| cytokine inducible SH2-containing protein 3 | AV374868 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.8 | 3.1 | 2.9 | 2.9 | 0 | 0 | 2.6 | 2.4 | 3.3 | 3.2 | 3.7 | 3.3 | 3.3 | 3.3 |
| myocyte enhancer factor 2C | AI426400 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.6 | −1 | −0.9 | 0 | 0 | −0.7 | −1.2 | 0 | −0.5 | −0.7 | −0.7 | −1.3 | −1.3 | −1.7 |
| Similar to rhodopsin (opsin 2, rod pigment) | M36699 | 0 | −0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.3 | 0 | −1.2 | −1.4 | −1.6 | −1.2 | −1.4 | −1.5 | −0.9 | −1.5 |
| hexokinase 2 | Y11666 | 0 | 0 | 0 | 0 | 0 | 0 | −0.5 | −0.7 | 0 | 0 | 0 | −0.7 | −0.4 | −1 | −1.3 | −1.2 | −1.3 | −1 | −1.2 | −1 | −0.6 | −1.2 |
| expressed sequence AA960287 | AW061237 | −0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.6 | 0 | 0 | −0.6 | 0 | −0.9 | −1 | −1.4 | −0.8 | −1.1 | −1.3 | −0.8 | −1.2 |
| rod outer segment membrane protein 1 | AV356715 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.4 | 0 | 0 | 0 | −0.3 | −0.6 | −0.6 | −1 | −0.9 | −1.5 | −1 | −1 | −1 | −0.6 | −0.9 |
| WNT1 inducible signaling pathway protein 1 | AF100777 | −0.4 | 0 | 0 | 0 | 0 | 0 | −0.3 | −0.5 | −0.6 | 0 | 0 | 0 | −0.6 | −0.9 | −0.8 | 0 | −0.9 | −1.1 | −1.4 | −1.4 | −1 | −1.5 |
| high mobility group box 2 | X67668 | 0 | 0 | −0.8 | 0 | 0 | 0 | 0 | −0.7 | −1.2 | 0 | 0 | 0 | −0.6 | −0.9 | −1.3 | −1 | 0 | 0 | −1 | −1 | −0.8 | 0 |
| ESTs | C78037 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.8 | 0 | 0 | 0 | −1.2 | 0 | −0.9 | −1.1 | −0.7 | −1.3 |
| kallikrein 9 | M17979 | 0.6 | 0 | 0 | −0.4 | 0 | −1.4 | 0 | −0.8 | −1.7 | −3.9 | 0 | −3.8 | −0.8 | 0 | −0.9 | −0.8 | −0.7 | 0 | −0.9 | 0 | −1.4 | −0.9 |
| ISL1 transcription factor, LIM/homeodomain, (islet-1) | AJ132765 | −0.2 | −0.5 | 0 | 0 | −0.3 | 0 | −0.5 | −0.7 | 0 | 0 | 0 | 0 | −0.8 | −1.5 | −0.6 | −0.5 | −0.7 | 0 | 0 | 0 | −0.7 | 0 |
| RIKEN cDNA 1110013B16 gene | AW123271 | 0 | 0 | −0.5 | 0 | 0 | −0.3 | 0 | 0 | 0 | 0 | −1.6 | 0 | −1.3 | −0.9 | −1.1 | −1.3 | −1.4 | −0.6 | −1.2 | −1.3 | −1.4 | −1.1 |
Figure 2Apoptosis map. Expression data of Rhok−/−/Sag−/− mice was overlaid onto a hypothetical apoptosis map using the GenMAPP (http://www.genmapp.org) program. Each rectangle represents a gene in the pathway. The number on the right of the rectangle corresponds to the log 2 ratio. Genes highlighted in yellow are unchanged. Pink and red denote upregulated genes while dark and light green correspond to downregulated genes. Rhok−/−/Sag−/− mice were exposed to 1 hour of low light (450 lux) and adapted for the indicated time period of darkness.
Figure 3CLASSIFI analysis was performed on mutant (Rhok−/−/Sag−/−). The significant cutoff use for this CLASSIFI analysis was 2.17×10-5, estimated using the Bonnferoni correction with an alpha of 0.05.